A Phase II Study of Intravenous Exatecan Mesylate (DX-8951f) Administered Daily for Five Days Every Three Weeks to Patients with Metastatic Adenocarcinoma of the Colon or Rectum

By Royce Melanie E.   Rowinsky Eric K.   Hoff Paulo M.   Coyle John   DeJager Robert   Pazdur Richard   Saltz Leonard B.  

Investigational New Drugs, Vol. 22, Iss. 1, 2004-01 ,pp. : 53-61

Springer Publishing Company

Access to resources Recommend Favorite

DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors

By Wente Moritz   Kleeff Jörg   Büchler Markus   Wanders Jantien   Cheverton Peter   Langman Stephen   Friess Helmut  

Investigational New Drugs, Vol. 23, Iss. 4, 2005-08 ,pp. : 339-347

Springer Publishing Company

Access to resources Recommend Favorite

Phase II Study of Perifosine in Previously Untreated Patients with Metastatic Melanoma

By Ernst D   Eisenhauer Elizabeth   Wainman Nancy   Davis Mary   Lohmann Reinhard   Baetz Tara   Belanger Karl   Smylie Michael  

Investigational New Drugs, Vol. 23, Iss. 6, 2005-12 ,pp. : 569-575

Springer Publishing Company

Access to resources Recommend Favorite

A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial

By Knowling M.   Blackstein M.   Tozer R.   Bramwell V.   Dancey J.   Dore N.   Matthews S.   Eisenhauer E.  

Investigational New Drugs, Vol. 24, Iss. 5, 2006-09 ,pp. : 435-439

Springer Publishing Company

Access to resources Recommend Favorite

A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancer

By Murren John   Modiano Manuel   Kummar Shivaani   Clairmont Caroline   Egorin Merrill   Chu Edward   Sznol Mario  

Investigational New Drugs, Vol. 23, Iss. 2, 2005-01 ,pp. : 123-135

Springer Publishing Company

Access to resources Recommend Favorite